DelveInsight’s, “Metastatic Renal Cell Carcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in the Metastatic Renal Cell Carcinoma pipeline landscape. It covers the Metastatic Renal Cell Carcinoma pipeline drug profiles, including Metastatic Renal Cell Carcinoma clinical trials and nonclinical stage products. It also covers the Metastatic Renal Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Metastatic Renal Cell Carcinoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Metastatic Renal Cell Carcinoma clinical trials studies, Metastatic Renal Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Metastatic Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Metastatic Renal Cell Carcinoma Pipeline Report
- DelveInsight’s Metastatic Renal Cell Carcinoma pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for Metastatic Renal Cell Carcinoma treatment.
- The leading Metastatic Renal Cell Carcinoma Companies includes AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4 Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd., Betta Pharmaceuticals, Exelixis, Hutchison Medipharma Limited, Sumitomo Pharma, NGM Biopharmaceuticals, Ocellaris Pharma, Oncorena AB, and others.
- Promising Metastatic Renal Cell Carcinoma Pipeline Therapies includes Olaparib, Atezolizumab, TP-1454, ALLO 316, SO-C101, VB10.NEO, PF-07209960, INCB001158, IPI-549, DSP-7888, Belzutifan, CD70 CAR-T, Sitravatinib, Pexastimogene Devacirepvec, Gevokizumab, AK104, CCT301-38, Pamiparib, ONC-392, Batiraxcept, AZD6738, NBTXR3, NKT2152, Bempegaldesleukin, Abemaciclib, Abexinostat, CM082, Savolitinib, Epacadostat, MEDI4736, XL092, Fruquintinib, DSP-7888, NGM 707, OC-001, Orellanine, and others.
- The Metastatic Renal Cell Carcinoma Companies and academics that are working to assess challenges and seek opportunities that could influence Metastatic Renal Cell Carcinoma R&D. The Metastatic Renal Cell Carcinoma pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.
To explore more information on the latest breakthroughs in the Metastatic Renal Cell Carcinoma Pipeline treatment landscape of the report, click here @ Metastatic Renal Cell Carcinoma Pipeline Outlook
Metastatic Renal Cell Carcinoma Overview
Renal cell carcinoma is the most common type of kidney cancer in adults. It accounts for approximately 85% of neoplasms arising from the kidney. Renal cell carcinoma may remain clinically occult for most of its course. Only 10% of patients present with the classic triad of flank pain, hematuria, and flank mass. Patients with renal cell cancer (RCC) develop metastatic spread in approximately 33% of cases. The clinical management of patients with metastatic RCC is complicated by the lack of significant efficacy from available therapies. Common sites of metastases include the lung, liver, bone, brain, and adrenal gland, with case reports detailing the capacity of RCC to appear almost anywhere in the body. More than one organ system is often involved in the metastatic process.
Latest Developmental Activities in the Metastatic Renal Cell Carcinoma Treatment Landscape
- In September 2022, The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present data from PROSPER RCC (EA8143), the first randomized Phase III trial of neoadjuvant immunotherapy in patients with kidney cancer. At a planned interim analysis, the trial showed no difference in recurrence-free survival (RFS) between arms in a population of patients that included both clear cell and non-clear cell subtypes, and was stopped early.
- In March 2022, Allogene Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) had granted Fast Track designation (FTD) to ALLO-316, the Company’s first AlloCAR T solid tumor clinical candidate for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). The FDA granted FTD based on the potential of ALLO-316 to address the unmet need for patients with difficult-to-treat renal cell carcinomas (RCC) who have failed standard RCC therapies.
- In February 2022, Eisai and Merck & Co., Inc., announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) had approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., for radically unresectable or metastatic renal cell carcinoma (RCC).
- In July 2021, City of Hope and Osel Inc. announced that the City of Hope had granted an exclusive worldwide license to Osel for intellectual property on the novel use of an LBP CBM588 to enhance the efficacy of checkpoint inhibitors to treat cancer, including metastatic renal cell carcinoma.
Metastatic Renal Cell Carcinoma Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
For further information, refer to the detailed Metastatic Renal Cell Carcinoma Unmet Needs, Metastatic Renal Cell Carcinoma Market Drivers, and Metastatic Renal Cell Carcinoma Market Barriers, click here for Metastatic Renal Cell Carcinoma Ongoing Clinical Trial Analysis
Metastatic Renal Cell Carcinoma Emerging Drugs Profile
Olaparib: AstraZeneca
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It was first approved by the FDA and EU in December 2014. Currently, it is in Phase II stage of clinical trial evaluation to treat metastatic Renal Cell Carcinoma.
Atezolizumab: Genentech
Atezolizumab is a humanized IgG antibody that binds PD-L1, preventing its interaction with PD-1 and B7-1. Preventing the interaction of PD-L1 and PD-1 removes inhibition of immune responses such as the anti-tumor immune response but not antibody dependent cellular cytotoxicity. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum based chemotherapy, or whose tumors do not respond to platinum based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. Currently, it is in Phase III stage of clinical trial evaluation to treat metastatic Renal Cell Carcinoma.
TP-1454: Sumitomo Dainippon Pharma
TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator,that is currently being evaluated in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors (NCT04328740). TP-1454 is the first PKM2 activator to be evaluated in cancer patients. Pyruvate kinase is the enzyme responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumor cells over the tumor immune microenvironment.
Metastatic Renal Cell Carcinoma Pipeline Therapeutics Assessment
There are approx. 40+ key companies which are developing the therapies for Metastatic Renal Cell Carcinoma. The companies which have their Metastatic Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Genentech.
Request a sample and discover the recent advances in Metastatic Renal Cell Carcinoma Ongoing Clinical Trial Analysis and Medications, click here @ Metastatic Renal Cell Carcinoma Treatment Landscape
Scope of the Metastatic Renal Cell Carcinoma Pipeline Report
- Coverage- Global
- Metastatic Renal Cell Carcinoma Companies- AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4 Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd., Betta Pharmaceuticals, Exelixis, Hutchison Medipharma Limited, Sumitomo Pharma, NGM Biopharmaceuticals, Ocellaris Pharma, Oncorena AB, and others.
- Metastatic Renal Cell Carcinoma Pipeline Therapies- Olaparib, Atezolizumab, TP-1454, ALLO 316, SO-C101, VB10.NEO, PF-07209960, INCB001158, IPI-549, DSP-7888, Belzutifan, CD70 CAR-T, Sitravatinib, Pexastimogene Devacirepvec, Gevokizumab, AK104, CCT301-38, Pamiparib, ONC-392, Batiraxcept, AZD6738, NBTXR3, NKT2152, Bempegaldesleukin, Abemaciclib, Abexinostat, CM082, Savolitinib, Epacadostat, MEDI4736, XL092, Fruquintinib, DSP-7888, NGM 707, OC-001, Orellanine, and others.
- Metastatic Renal Cell Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action
Dive deep into rich insights for drugs for Metastatic Renal Cell Carcinoma Market Drivers and Metastatic Renal Cell Carcinoma Market Barriers, click here @ Metastatic Renal Cell Carcinoma Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Metastatic Renal Cell Carcinoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Metastatic Renal Cell Carcinoma – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Atezolizumab: Genentech
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Olaparib: AstraZeneca
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- TP-1454: Sumitomo Dainippon Pharma
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Metastatic Renal Cell Carcinoma Key Companies
- Metastatic Renal Cell Carcinoma Key Products
- Metastatic Renal Cell Carcinoma- Unmet Needs
- Metastatic Renal Cell Carcinoma- Market Drivers and Barriers
- Metastatic Renal Cell Carcinoma- Future Perspectives and Conclusion
- Metastatic Renal Cell Carcinoma Analyst Views
- Metastatic Renal Cell Carcinoma Key Companies
- Appendix
Got Queries? Find out the related information on Metastatic Renal Cell Carcinoma Mergers and acquisitions, Metastatic Renal Cell Carcinoma Licensing Activities @ Metastatic Renal Cell Carcinoma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services